No 1394/2007 on ATMPs, which provides foundational concepts for the development and supervision of these products.

Directive 2001/83/EC and its amendments outline requirements for pharmacovigilance across medicinal products in the EU.

FDA’s REMS (Risk Evaluation and Mitigation Strategies) guidance, which incorporates pharmacovigilance elements tailored specifically for ATMPs.

It is crucial to note that both regulators require pharmacovigilance systems to be in place at the time of product approval but differ in their specific expectations regarding submissions, operational practices, and the scope of the pharmacovigilance activities.

Step 2: Developing a Risk Management Plan (RMP)

A Risk Management Plan (RMP) is an essential document for both EMA and FDA regulatory submissions. The RMP outlines how a company plans to identify, characterize, prevent, and minimize risks associated with a medicinal product, particularly relevant to ATMPs given their inherent risks.

To develop an effective RMP, the following steps should be undertaken:

• Identify Potential Risks: Start by conducting literature reviews, preclinical and clinical studies, and any existing safety data to identify all potential safety concerns related to the ATMP. Include both serious and non-serious adverse reactions.
• Assess Risks: Evaluate the identified risks in terms of their potential impact on patient health and safety. This assessment should incorporate pharmacological data, epidemiological studies, and any related findings from similar therapeutic contexts.
• Develop Risk Minimization Strategies: Define actions that will be taken to mitigate identified risks, such as safety monitoring, labeling updates, educational interventions for healthcare providers and patients, and conditions for distribution.
• Document Plans for Post-Authorization Safety Studies (PASS): If additional studies are necessary to further understand the safety profile of the ATMP, outline these studies as part of the RMP.

EMA requires the submission of the RMP as part of the marketing authorization application (MAA), while the FDA may request a RMP as part of the REMS. Consult the latest guidelines from the EMA and FDA regarding the formatting and contents required for these documents, as failure to comply can lead to delays in approval.

Step 3: Establishing a Pharmacovigilance System

A robust pharmacovigilance system is crucial for effective monitoring of safety data throughout the lifecycle of an ATMP. The system should be designed to collect, assess, analyze, manage, and report adverse events associated with the product post-marketing.

The following steps outline the establishment of a pharmacovigilance system:

• Assign Pharmacovigilance Responsibilities: Designate a qualified personnel responsible for the overall management of pharmacovigilance activities, including a Pharmacovigilance Officer, who should have a profound understanding of applicable regulations and therapeutic areas.
• Implement Data Collection Mechanisms: Establish procedures for collecting safety information from various sources, including clinical trials, spontaneous reports, literature, and registries. Utilize Healthcare Professional (HCP) reporting, patient reporting systems, and electronic medical records as sources for safety data. A secure and validated database for storing and handling these reports is essential.
• Conduct Adverse Event Reporting: Ensure compliance with required reporting timelines and formats. The FDA and EMA have guidelines indicating specific time frames post-event occurrence for reporting. Ensure that your system can meet these timelines effectively.
• Analyze and Signal Detection: Regularly analyze the collected safety data to identify any signals or trends in adverse events. Utilize established methodologies such as disproportionality analysis to evaluate the relative risk and identify potential safety issues early.
• Communicate Findings: Develop a system for communicating safety findings to stakeholders, including regulatory authorities, healthcare professionals, and patients. Include plans for risk communication when significant safety issues arise.

Regulatory authorities may require periodic safety update reports (PSURs) to summarize the safety data collected and the drug’s benefit-risk balance, which should also feature prominently within your pharmacovigilance system.

Step 4: Incorporating Post-Marketing Surveillance Strategies

Post-Marketing Surveillance (PMS) is critical for assessing the long-term efficacy and safety of ATMPs following their release in the market. It allows for the identification of rare adverse events that may not have been evident during clinical trials.

Establishing PMS can be approached through several key strategies:

• Design Registries: Develop disease and treatment registries to monitor the long-term outcomes of ATMPs. These registries can provide invaluable data on the real-world effectiveness and safety profile of products across diverse populations.
• Conduct PASS: Implement the additional studies identified in your RMP. These studies should be well-defined in terms of objective, design, methodology, and duration. Collect data in compliance with good clinical practice standards.
• Utilize Electronic Health Records (EHR): Leverage EHR data to monitor patient safety and treatment outcomes associated with ATMP use. Collaborate with healthcare providers to ensure reporting of relevant information.
• Engage in Risk Minimization Activities: Ensure that healthcare providers and patients are well-educated regarding the use of the ATMP. Provide training sessions, informational brochures, and safety warnings as applicable.

The information generated from PMS activities can feed back into your increasingly iterative RMP, adjusting your strategies based on the realities encountered once the product is in use.

Step 5: Implementing Labeling Updates and Safety Communications

Once an ATMP is marketed, continuous monitoring may necessitate updates to product labeling and safety communications. This ensures that healthcare professionals and patients possess the most up-to-date information regarding risks, benefits, and any emerging safety concerns.

The implementation of labeling updates can follow these steps:

• Assess Current Labeling Requirements: Review existing product labeling to ensure it accurately reflects current safety data, indications for use, and any contraindications or precautions identified.
• Prepare Updates: Draft the necessary updates based on the collected safety data. This may involve modifying text to better communicate risks or highlighting newly identified benefits.
• Submit Labeling Changes for Regulatory Review: Submit proposed labeling updates to the FDA or EMA, as applicable. In the United States, updates that are deemed to be necessary for safety must comply with Section 505(o) of the Federal Food, Drug, and Cosmetic Act, while updates in Europe would align with the requirements in the Notice to Marketing Authorization Holders.
• Communicate Updates: Ensure healthcare professionals and patients are informed of the changes through direct notifications, updates on company websites, and announcements via professional medical associations.

Regular interaction with regulatory bodies is essential at every step, focusing on transparent communication regarding risk management and safety updates tailored to the unique nature of ATMPs.

Conclusion: Integrating Pharmacovigilance Planning into ATMP Lifecycle Management

Pharmacovigilance planning for ATMPs is an integral part of product lifecycle management, requiring a proactive approach to safety monitoring and risk management. Effective pharmacovigilance not only fulfills regulatory obligations but also aids in ensuring patient safety and fostering public trust in innovative therapies.

By understanding regulatory frameworks, developing a comprehensive RMP, establishing robust pharmacovigilance systems, incorporating effective PMS strategies, and implementing timely labeling updates, stakeholders can adeptly navigate compliance with EMA and FDA requirements. This meticulous approach will foster the responsible advancement of ATMPs, ensuring that they deliver their intended benefits without compromising patient safety.